Publications

Sort by: Date | Author | Title

Wedge, E., Hansen, J. W., Garde, C., Asmar, F., Tholstrup, D., Kristensen, S. S., Munch-Petersen, H. D., Ralfkiaer, E., Brown, P., Grønbæk, K. & Kristensen, L. S. (2017). Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma. American Journal of Hematology, 92(7), 689-694. https://doi.org/10.1002/ajh.24751
Kristensen, L. S., Michaelsen, S. R., Dyrbye, H., Aslan, D., Grunnet, K., Christensen, I. J., Poulsen, H. S., Grønbæk, K. & Broholm, H. (2016). Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. Journal of Neuropathology and Experimental Neurology, 75(3), 246-255. https://doi.org/10.1093/jnen/nlv024
Hansen, J. W., Westman, M. K., Sjö, L. D., Saft, L., Kristensen, L. S., Ørskov, A. D., Treppendahl, M., Andersen, M. K. & Grønbaek, K. (2016). Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. American Journal of Hematology, 91(12), 1234-1238. https://doi.org/10.1002/ajh.24554
Munch-Petersen, H. D., Asmar, F., Dimopoulos, K., Areškevičiūtė, A., Brown, P., Girkov, M. S., Pedersen, A., Sjö, L. D., Heegaard, S., Broholm, H., Kristensen, L. S., Ralfkiaer, E. & Grønbæk, K. (2016). TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathologica Communications, 4, 40. https://doi.org/10.1186/s40478-016-0307-6
Aslan, D., Garde, C., Nygaard, M. K., Helbo, A. S., Dimopoulos, K., Hansen, J. W., Severinsen, M. T., Treppendahl, M. B., Sjø, L. D., Grønbæk, K. & Kristensen, L. S. (2016). Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations. OncoTarget, 7(9), 9951-9963. https://doi.org/10.18632/oncotarget.7127
Helbo, A. S., Treppendahl, M., Aslan, D., Dimopoulos, K., Nandrup-Bus, C., Holm, M. S., Andersen, M. K., Liang, G., Kristensen, L. S. & Grønbæk, K. (2015). Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients. Genes, 6(4), 977-90. https://doi.org/10.3390/genes6040977
Kristensen, L. S., Myrtue Nielsen, H. & Hansen, L. L. (2009). Epigenetics and cancer treatment. European Journal of Pharmacology, 625(1 - 3), 131 - 142.
Dobrovic, A. & Kristensen, L. S. (2008). DNA methylation, epimutations and cancer predisposition. International Journal of Biochemistry & Cell Biology, 41(1), 34-9. https://doi.org/10.1016/j.biocel.2008.09.006